ClinicalTrials.gg
RecruitingNCT07290140RESTORE-2 RCTUpdated Oct 29, 2026

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

An interventional study of Airiver ESSpand DCB and ESS in Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps, sponsored by Airiver Medical, Inc.. Recruiting at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Airiver Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 29, 20266 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Planned enrollment
7th of 71
300 · median 60
Started
2026
with 6 others
No phase
14 of 83
5 open now
Primary completion
2028-03
later than 14 of 19 live
Registered
77th of 83
by date

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 7th largest by planned enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 with no phase, reaches primary completion later than 14 of the 19 other live ones, and was the 77th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, controlled, double-blind clinical trial enrolling 300 adult subjects with chronic rhinosinusitis (CRS) with and without nasal polyps (CRSwNP and CRSsNP) indicated for endoscopic sinus surgery (ESS).

Read the detailed description

Subjects will be randomized in a 1:1 ratio for ESS with no additional treatment (control group) or ESS followed by Airiver ESSpand DCB sinus dilation of affected sinuses (treatment group) at up to 40 US based sites.

03

Conditions studied

  • Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥18 years
  2. Confirmed diagnosis of CRS per the 2021 "International Consensus Statement on Allergy and Rhinology: Rhinosinusitis" definition.
  3. Radiographic evidence of bilateral ethmoid disease on CT taken 6 months or less prior to study index procedure and at least 6 months after any prior ESS or nasal surgery, polypectomy, balloon sinus dilation, etc. as applicable
  4. Radiographic evidence of bilateral frontal sinus and/or frontal sinus outflow tract disease
  5. Baseline SNOT-22 score ≥ 30
  6. Has failed previous medical treatment and is an appropriate candidate for primary or revision ESS of bilateral ethmoid sinuses and bilateral frontal/frontal sinus outflow tract
  7. Willing and able to provide written
  8. Willing and able to comply with all protocol follow up visits and assessments

Exclusion criteria

Exclusion Criteria:

  1. Nasal cavity tumor (malignant or benign)
  2. Antrochoanal polyps
  3. Previous complete middle turbinate resection
  4. Clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on CT scan, necrotic sinus tissue)
  5. History of prior lamina dehiscence or cerebrospinal fluid (CSF) leak in skull-based dehiscence
  6. Concurrent condition requiring active chemotherapy and/or immunotherapy management
  7. Subjects whose symptoms are too severe to undergo ESS (e.g., temperature >102.5F or extra-sinus manifestations, such as orbital cellulitis; dental or facial or brain abscess; cavernous vein thrombosis; or altered mental status
  8. History of complications from prior ESS or balloon dilation procedure (e.g., CSF leak or injury to the skull base or orbital injury)
  9. History of primary ciliary dyskinesia
  10. Oral- dependent conditions such as (COPD) or other conditions
  11. Have evidence of significant baseline mucosal injury, ulceration, or erosion (e.g., exposed cartilage, perforation) on nasal examination
  12. Acute purulent nasal infection or upper respiratory tract infection, including but not limited to acute bacterial rhinosinusitis (ABRS), acute rhinosinusitis (ARS), or COVID -19 within 2 weeks before the baseline visit.
  13. Allergy or to paclitaxel or structurally related compounds.
  14. Subject has taken biologic drugs in the 6 months leading up to the screening visit or who expect to take biologics in the next 24 months.
  15. Subject has taken oral corticosteroids in the 30 days leading up to their baseline appointment.
  16. Subject who plans to undergo posterior nasal nerve ablation in the next 24 months.
  17. Subject has a history of inability to tolerate nasal endoscopy
  18. Concurrent medical condition that would affect the investigator's ability to evaluate the subject's condition or that could compromise subject safety, such as severe COPD, severe asthma
  19. Pregnant or planning to become pregnant during the first 12 months of enrollment in the study
  20. Subject who has undergone a nasal/sinus surgery including but not limited to ESS, polypectomy, septoplasty, turbinoplasty, balloon sinus dilation, placement of steroid releasing implants, posterior nasal nerve ablation in the 6 months prior to the baseline appointment.
  21. Previous Draf III frontal sinus surgery or a study index procedure ESS is expected to be or is a Draf III sinus surgery.
  22. Subject whose index procedure did not include bilateral ethmoid ESS and bilateral frontal ESS
  23. Subject whose expected study index procedure includes steroid releasing implants or non-resorbable nasal packing/stents.
  24. Subject whose study index procedure is aborted for any reason
  25. \<2 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    • Treatment with the Airiver ESSpand DCB and ESS

    Subjects will have ESSpand DCB dilation of the ESS treated sinuses

  • Active comparator
    Treatment with ESS

    Subjects will have ESS treatment at target sinuses

    Procedure: ESS

Interventions

  • Combination productAiriver ESSpand DCB

    The investigational procedure will be ESSpand DCB dilation of all surgically treated sinuses, including the resected ethmoid sinus cavities. Note: Prior to randomization to the investigational procedure, all subjects will undergo traditional ESS of their diseased sinuses.

  • ProcedureESS

    traditional ESS treatment of diseased sinuses.

06

What researchers measure

Primary outcomes

  1. Primary safety

    Incidence of major adverse events (MAE) through 30 days post-index treatment.

    Time frame: 30 days post- index procedure

  2. Primary efficacy endpoint

    Reduction in need for postoperative intervention in the ethmoid and /or frontal sinus within 6 months post-index procedure.

    Time frame: 6 months post-index procedure

Secondary outcomes

  1. Hypothesis tested clinical responder rate at 12 months

    a responder is defined as a subject who has not undergone revision ESS, balloon sinus dilation, or any other procedural intervention, or received oral/systemic steroid or biologic therapy for CRS in the follow-up period, and with SNOT-22 score change from baseline (CFBL) by ≥8.9 points

    Time frame: 12 months

  2. Hypothesis tested mean adhesion/scaring grade of sphenoid sinus at 6 months, as assessed by the independent, blinded reviewer

    Grading 0 to 3, the higher grade indicates significant scarring and adhesion

    Time frame: 6 months

07

Study locations

16 of 16 sites recruiting
  • University of Alabama
    Birmingham, Alabama 35233, United States
    Recruiting
    • Michelle Osoinak · Contactmosoinak@uabmc.edu · 205-539-2903
    • Do-Yeon Cho, MD · Principal investigator
  • Excel ENT
    Birmingham, Alabama 35244, United States
    Recruiting
  • North Alabama ENT
    Huntsville, Alabama 35801, United States
    Recruiting
  • SENTA Clinica
    San Diego, California 92108, United States
    Recruiting
    • Alen Putros · Contactaputrosent@gmail.com · 619-977-9873
    • Brian Weeks, MD · Principal investigator
  • Colorado ENT & Allergy
    Colorado Springs, Colorado 80923, United States
    Recruiting
  • Physicians' Clinic of Iowa
    Cedar Rapids, Iowa 52403, United States
    Recruiting
    • Cassidy Holub · ContactCMHOLUB@PCOFIOWA.COM · 319-247-3474
    • Thomas Heineman, MD · Principal investigator
  • KUMC
    Kansas City, Kansas 66160, United States
    Recruiting
    • Bryan Humphrey · Contactbhumphrey@kumc.edu · 913-588-3759
    • Vidur Bhalla, MD · Principal investigator
  • Advanced ENT
    Louisville, Kentucky 40220, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
    • Stelby Augustine, RN · ContactSTAUGUST@montefiore.org · 718-920-7054
    • Christina Fang, MD · Principal investigator
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Charleston ENT & Allergy
    Charleston, South Carolina 29406, United States
    Recruiting
  • MUSC - Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Shaun Nguyen, MD · Contactnguyensh@musc.edu · (843)792-1356
    • Rodney Schlosser, MD · Sub investigator
  • Dallas ENT
    Dallas, Texas 75244, United States
    Recruiting
  • Ear and Sinus Institute
    Fort Worth, Texas 76104, United States
    Recruiting
  • ENT Associates of Texas
    McKinney, Texas 75070, United States
    Recruiting
  • University of Virginia
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Elena Squire · ContactEM8ZK@uvahealth.org · 434-243-3607
    • Jose Mattos, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 18, 2025
StartActual
Jun 1, 2026
Primary completionEst.
Mar 28, 2028
CompletionEst.
Mar 1, 2031
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (6 United States)
  • University of Alabama · Birmingham, United States
  • North Alabama ENT · Huntsville, United States
  • KUMC · Kansas City, United States
  • Montefiore Medical Center · The Bronx, United States
  • Ear and Sinus Institute · Fort Worth, United States
  • ENT Associates of Texas · McKinney, United States
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Colorado ENT & Allergy · Colorado Springs, United StatesContact m•••@coloradoent.com · •••7889→e•••@coloradoent.com · •••7889
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    6 sites added
    Show 6 added (6 United States)
    • University of Alabama · Birmingham, United States
    • North Alabama ENT · Huntsville, United States
    • KUMC · Kansas City, United States
    • Montefiore Medical Center · The Bronx, United States
    • Ear and Sinus Institute · Fort Worth, United States
    • ENT Associates of Texas · McKinney, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Colorado ENT & Allergy · Colorado Springs, United StatesContact m•••@coloradoent.com · •••7889→e•••@coloradoent.com · •••7889
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07290140
Lead sponsor
Airiver Medical, Inc.
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Jun 1, 2026
Primary completion
Mar 28, 2028 (estimated)
Completion
Mar 1, 2031 (estimated)
Last update
Oct 29, 2026

Study contacts

Sr Clinical Operation Director
Contact
myersj@airiver.com
6123250226
Chief Operation Officer
Contact
vajgrtp@airiver.com
Noem Cohen, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion